To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration

HK inno.N

Status and phase: Completed; Phase 1

Conditions: Pharmacodynamic; Pharmacokinetic; Drug Interaction

Treatments: Drug: CJ-12420 100mg; Drug: CJ-12420 50mg; Drug: AMX 1g; Drug: CLR 500mg; Drug: Pantoprazole 40mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT03011996

CJ_APA_107

Details and patient eligibility

About

Cohort 1

To evaluate the pharmacokinetic interactions of CJ-12420 after multiple oral doses of CJ-12420 given alone or in combination with amoxicillin/clarithromycin in healthy subjects.

Cohort 2

To evaluate the pharmacodynamic profiles of CJ-12420 after multiple oral doses of CJ-12420 in combination with amoxicillin/clarithromycin in healthy subjects as compared to an active control group, i.e., pantoprazole in combination with amoxicillin/clarithromycin.

Full description

To evaluate the pharmacokinetic the drug-drug interaction of CJ-12420 and amoxicillin/clarithromycin and investigate the pharmacodynamic of co-administration of CJ-12420 and amoxicillin and clarithromycin.

Enrollment: 60 patients

Sex: All

Ages: 19 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy male volunteers aged ≥19 and ≤45 years at screening;
2. No congenital or chronic disease, and no morbid symptoms or findings on screening tests;
3. Body mass index (BMI) ≥18.5 and ≤28 kg/m2;
4. Considered eligible based on medical examinations (including interview, vital signs, 12-lead ECG, physical exam and laboratory tests) which are set and performed in accordance with the nature of investigational product by the investigator;
5. Voluntary consent to participate in the study after being fully informed of purpose and procedures of the study, and profiles of investigational product prior to the participation;
6. For Cohort 2, positive on 13C urea breath test.

Exclusion criteria

1. Medical history

   1. History or current evidence for diseases considered clinically relevant by the investigator including hepatic, renal, gastrointestinal, respiratory, musculoskeletal, endocrine, neurologic, hemato-oncological, urinary, or cardiovascular (including cardiac arrhythmia) diseases;
   2. History of gastrointestinal diseases (such as gastritis, gastrodynia, gastroesophageal reflux disease, Crohn's disease and ulcer) or abdominal surgery (except for simple appendectomy or herniotomy) which are considered to have potential effect on drug absorption by the investigator;
   3. For Cohort 2, previous treatment failure for H. pylori eradication.

2. Laboratory tests and ECG

   1. AST or ALT ≥ 1.25 x upper limit of normal (ULN);
   2. Total bilirubin ≥ 1.5 x ULN;
   3. eGFR calculated by CKD-EPI formula < 80 mL/min;
   4. Any clinically relevant ECG abnormalities.

3. Allergy and drug abuse

   1. History of hypersensitivity to drugs containing investigational products (penicillins, cephems, macrolides, pantoprazole and benzimidazole) and other drugs (including aspirin and antibiotics);
   2. History of drug abuse or positive on drug screening test.

4. Drug/dietary restrictions

   1. Medications (including herbal supplements) or abnormal diet (e.g., grapefruit juice > 1 L/day, excessive garlic, broccoli, kale, etc.) which may have effect on absorption, distribution, metabolism and excretion of investigational products within 28 days prior to the first study dose;
   2. Use of prescription drugs, over-the-counter drugs (OTCs) or vitamins within 10 days prior to the first study dose;
   3. Participating in other study and receive investigational product within 3 months prior to the first study dose.

5. Blood donation and transfusion

   1. Whole blood donation within 60 days prior to the first study dose;
   2. Donation of blood components or transfusion within 30 days prior to the first study dose.

6. Pregnancy and contraception

   1. Pregnant or breast-feeding;
   2. Subject or his partner's inability to use of medically qualifying dual-contraceptive methods or medically acceptable contraception (including intrauterine device with established pregnancy failure rate, barrier methods with spermicide, vasectomy, tubectomy, tubal ligation and hysterectomy) from screening to 30 days of the last dose of investigational product.

7. Others

   1. Heavy use of alcohol (average alcohol intake ≥30 g/day) or positive on alcohol test;
   2. Heavy smoker (>10 cigarettes/day);
   3. Caffeine intake > 400 mg/day;
   4. Any clinically relevant findings considered inappropriate for study participation at the discretion of the investigator.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

60 participants in 6 patient groups

CJ-12420 100mg

Experimental group

Description:

CJ-12420 100mg BID for 5 days

Treatment:

Drug: CJ-12420 100mg

CJ-12420 50mg + CLR 500mg + AMX 1g

Experimental group

Description:

coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days

Treatment:

Drug: AMX 1g

Drug: CLR 500mg

Drug: CJ-12420 50mg

Pantoprazole 40mg + CLR 500mg + AMX 1g

Active Comparator group

Description:

coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days

Treatment:

Drug: AMX 1g

Drug: CLR 500mg

Drug: Pantoprazole 40mg

CJ-12420 100mg + CLR 500mg + AMX 1g

Experimental group

Description:

coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days

Treatment:

Drug: AMX 1g

Drug: CLR 500mg

Drug: CJ-12420 100mg

CLR 500mg/AMX 1g

Experimental group

Description:

CLR 500mg/AMX 1g BID for 5 days

Treatment:

Drug: AMX 1g

Drug: CLR 500mg

CJ-12420 100mg + CLR 500mg/AMX 1g

Experimental group

Description:

coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days

Treatment:

Drug: AMX 1g

Drug: CLR 500mg

Drug: CJ-12420 100mg